| __timestamp | Bio-Techne Corporation | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 117418000 |
| Thursday, January 1, 2015 | 144969000 | 102526000 |
| Friday, January 1, 2016 | 162364000 | 105386000 |
| Sunday, January 1, 2017 | 188462000 | 110188000 |
| Monday, January 1, 2018 | 210850000 | 121544000 |
| Tuesday, January 1, 2019 | 240515000 | 127930000 |
| Wednesday, January 1, 2020 | 255497000 | 148917000 |
| Friday, January 1, 2021 | 298182000 | 440760000 |
| Saturday, January 1, 2022 | 349103000 | 540517000 |
| Sunday, January 1, 2023 | 366887000 | 435577000 |
| Monday, January 1, 2024 | 389335000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the biotech and pharmaceutical industries, understanding cost dynamics is crucial. Bio-Techne Corporation and Jazz Pharmaceuticals plc, two prominent players, have shown distinct trends in their cost of revenue from 2014 to 2023. Bio-Techne's cost of revenue has surged by approximately 266%, reflecting a steady growth trajectory. In contrast, Jazz Pharmaceuticals experienced a dramatic spike in 2021, with costs peaking at 440% of their 2014 levels, before slightly declining in 2023. This fluctuation highlights the volatile nature of pharmaceutical operations, often driven by R&D investments and market expansions. Notably, data for 2024 is incomplete, indicating potential shifts in Jazz Pharmaceuticals' financial strategies. As these companies navigate the complexities of their respective markets, stakeholders must remain vigilant, adapting to the financial ebbs and flows that define this dynamic sector.
Cost Insights: Breaking Down Eli Lilly and Company and Bio-Techne Corporation's Expenses
Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Jazz Pharmaceuticals plc
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Jazz Pharmaceuticals plc
BeiGene, Ltd. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Bio-Techne Corporation vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Mesoblast Limited
Cost of Revenue: Key Insights for Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Lantheus Holdings, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc.
Cost of Revenue Trends: Jazz Pharmaceuticals plc vs Viridian Therapeutics, Inc.